Patents by Inventor Stephen W Kaldor

Stephen W Kaldor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-peptidyl vasopressin V1a antagonists
    Patent number: 6204260
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl)acetic acid derivatives for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: March 20, 2001
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin DG Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
    Patent number: 6162812
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: December 19, 2000
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Polymer bound carbodiimide coupling reagent
    Patent number: 6126932
    Abstract: This invention provides novel 5-HT.sub.1F agonists of Formula ##STR1## where X, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification, which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: October 3, 2000
    Assignee: Eli Lilly and Company
    Inventors: James E Fritz, Patric J Hahn, Stephen W Kaldor, Miles G Siegel, Yao-Chang Xu
  • Anti-viral method
    Patent number: 6060484
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: May 9, 2000
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Stephen W. Kaldor, Jeffrey A. Kyle, John E. Munroe
  • Carbodiimide coupling reagent
    Patent number: 5998630
    Abstract: The present invention relates to compounds used for increasing activation of the 5-HT1F receptor.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: December 7, 1999
    Assignee: Eli Lilly and Company
    Inventors: James E Fritz, Patric J Hahn, Stephen W Kaldor, Miles G Siegel, Yao-Chang Xu
  • HIV protease inhibitors
    Patent number: 5952343
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 14, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • N-?2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT.sub.1F agonists
    Patent number: 5942536
    Abstract: The invention provides novel 5-HT.sub.1f agonists of formula (I) where X, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification, which are useful for the treatment of migraine and associate disorders.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: August 24, 1999
    Assignee: Eli Lilly and Company
    Inventors: James E Fritz, Patric J Hahn, Stephen W Kaldor, Miles G Siegel, Yao-Chang Xu
  • HIV protease inhibitors
    Patent number: 5846993
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 8, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Stephen W. Kaldor, Vincent J. Kalish, Siegfried Heinz Reich, John H. Tatlock, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 5834467
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 10, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Vincent J. Kalish, Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriquez
  • HIV protease inhibtors
    Patent number: 5827891
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 27, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Anti-picornaviral agents
    Patent number: 5821331
    Abstract: The present invention provides a group of novel compounds that inhibit the proteolytic activity of 3C proteases which are found in picornaviruses, particularly rhinoviruses. In picornaviruses the RNA genome is translated into a single large viral polyprotein precursor. The precursor demonstrates auto-proteolytic activity, cleaving itself into mature viral gene products. Therefore, compounds of the current invention are particularly useful in treating picornaviral infections by interrupting the processing of the viral gene products into mature and infectious viral particles. The current invention also provides a novel process the preparation of compounds of the current invention. The process entails the selective reduction of an imide intermediate representing a marked improvement over processes known in the art for making peptidyl-aldehydes.
    Type: Grant
    Filed: February 8, 1996
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Marlys Hammond, Stephen W. Kaldor
  • Serotonin 5-HT.sub.1F agonists
    Patent number: 5792763
    Abstract: This invention provides novel 5-HT.sub.1F agonists of formula ##STR1## where X, Y, Z,and R are defined in the specification, which are useful for the prevention and treatment of migraine and associated disorders.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: August 11, 1998
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Stephen W. Kaldor, Sidney Xi Liang, Upinder Singh, Yao-Chang Xu
  • Intermediates for inhibitors of HIV protease and method of preparation thereof
    Patent number: 5719287
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of their use.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 17, 1998
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Kaldor, Marlys Hammond
  • Anti-picornaviral agents
    Patent number: 5514778
    Abstract: The present invention provides a group of novel compounds that inhibit the proteolytic activity of 3C proteases which are found in picornaviruses, particularly rhinoviruses. In picornaviruses the RNA genome is translated into a single large viral polyprotein precursor. The precursor demonstrates auto-proteolytic activity, cleaving itself into mature viral gene products. Therefore, compounds of the current invention are particularly useful in treating picornaviral infections by interrupting the processing of the viral gene products into mature and infectious viral particles. The current invention also provides a novel process the preparation of compounds of the current invention. The process entails the selective reduction of an imide intermediate representing a marked improvement over processes known in the art for making peptidyl-aldehydes.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: Marlys Hammond, Stephen W. Kaldor
  • Intermediates for preparing HIV protease inhibitors
    Patent number: 5514802
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Marlys Hammond, Stephen W. Kaldor
  • Retroviral protease inhibitors
    Patent number: 5508407
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of their use.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: April 16, 1996
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Kaldor, Marlys Hammond
  • Inhibitors of HIV protease useful for the treatment of AIDS
    Patent number: 5491166
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: February 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Kaldor, Thomas E. Mabry
  • HIV protease inhibitors
    Patent number: 5484926
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: January 16, 1996
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried H. Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Inhibitors of HIV protease useful for the treatment of AIDS
    Patent number: 5475136
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: December 12, 1995
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Stephen W. Kaldor, Marlys Hammond, Krzysztof Appelt
  • Inhibitors of HIV protease
    Patent number: 5434265
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating HIV infection.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: July 18, 1995
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Marlys Hammond, Stephen W. Kaldor